Drug Type Small molecule drug |
Synonyms CS-08399 |
Target |
Action inhibitors |
Mechanism MTA-PRMT5 inhibitors(MTA-Cooperative PRMT5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Lymphoma | Phase 1 | China | 03 Jun 2026 | |
| Methylthioadenosine phosphorylase deletion cancer | Phase 1 | China | 03 Jun 2026 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 01 Jun 2026 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Jun 2026 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 01 Jun 2026 | |
| Pancreatic adenocarcinoma | Phase 1 | China | 01 Jun 2026 |





